Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data

Group 1 - Pfizer Inc. is included in a Dividend Stock Portfolio, highlighting its potential for income generation [1] - Guggenheim Partners raised its price target for Pfizer to $36 from $35, maintaining a Buy rating, with an estimated upside of about $2 per share based on upcoming Phase 3 trial data [2] - Pfizer and Valneva reported that their Lyme disease vaccine demonstrated over 70% efficacy in a late-stage study, with a confirmed efficacy of 73.2% after the fourth dose [3][4] Group 2 - The Lyme disease vaccine trial initially showed a confidence interval of 15.8%, but a subsequent analysis met the required threshold, allowing Pfizer to proceed with regulatory submissions [4] - Pfizer is characterized as a research-driven global biopharmaceutical company focused on the discovery, development, manufacturing, and distribution of medicines [5]